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Abstract
Background: Central post-stroke pain (CPSP) is a neuropathic pain syndrome associated with somatosensory
abnormalities due to central nervous system lesion following a cerebrovascular insult. Post-stroke pain (PSP) refers
to a broader range of clinical conditions leading to pain after stroke, but not restricted to CPSP, including other
types of pain such as myofascial pain syndrome (MPS), painful shoulder, lumbar and dorsal pain, complex regional
pain syndrome, and spasticity-related pain. Despite its recognition as part of the general PSP diagnostic possibilities,
the prevalence of MPS has never been characterized in patients with CPSP patients. We performed a cross-sectional
standardized clinical and radiological evaluation of patients with definite CPSP in order to assess the presence of
other non-neuropathic pain syndromes, and in particular, the role of myofascial pain syndrome in these patients.
Methods: CPSP patients underwent a standardized sensory and motor neurological evaluation, and were classified
according to stroke mechanism, neurological deficits, presence and profile of MPS. The Visual Analogic Scale (VAS),
McGill Pain Questionnaire (MPQ), and Beck Depression Scale (BDS) were filled out by all participants.
Results: Forty CPSP patients were included. Thirty-six (90.0%) had one single ischemic stroke. Pain presented during
the first three months after stroke in 75.0%. Median pain intensity was 10 (5 to 10). There was no difference in pain
intensity among the different lesion site groups. Neuropathic pain was continuous-ongoing in 34 (85.0%) patients
and intermittent in the remainder. Burning was the most common descriptor (70%). Main aggravating factors were
contact to cold (62.5%). Thermo-sensory abnormalities were universal. MPS was diagnosed in 27 (67.5%) patients
and was more common in the supratentorial extra-thalamic group (P <0.001). No significant differences were
observed among the different stroke location groups and pain questionnaires and scales scores. Importantly, CPSP
patients with and without MPS did not differ in pain intensity (VAS), MPQ or BDS scores.
Conclusions: The presence of MPS is not an exception after stroke and may present in association with CPSP as a
common comorbid condition. Further studies are necessary to clarify the role of MPS in CPSP.
Background
Central poststroke pain (CPSP) is a neuropathic pain
syndrome associated with somatosensory abnormalities
due to central nervous system (CNS) lesion following a
cerebrovascular insult. CPSP pain has been reported
since the end of the XIX century [1]. Classically
described after vascular lesions in the thalamus [2], CPSP
is also common in lesions of the dorso-lateral medulla
[3], thalamic-capsular [4], and parietal regions [5]. It can
be a consequence of lesions located anywhere along the
telencephalon involving the somatosensory pathways
[6,7]. It has been demonstrated that multiple vascular en-
cephalic lesions are present in the majority of CPSP
patients [4].
Poststroke pain (PSP) refers to a broader range of clin-
ical conditions leading to pain after stroke, but not
restricted to pain of central neuropathic nature (CPSP).
PSP affects from 11 to 55% of patients following a CNS
vascular event [8-10]. It includes several painful
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conditions such as CPSP, painful shoulder, lumbar and
dorsal pain, complex regional pain syndrome, tension
type headache and spasticity-related pain [10-12]. In par-
ticular, musculoskeletal pain is prevalent in PSP patients
[13], being probably secondary to decreased muscle
strength and altered descending modulatory system
tonus [14]. Myofascial pain syndrome (MPS) is defined
by the occurrence of regional pain and stiffness, limited
range of motion in the affected muscle, satellite trigger
points and twitch response to palpation of taut bands in
the muscles [15,16].
MPS can also serve as a peripheral pain generator and
alter the function of descending modulatory pathways as
has been recently reported in other chronic pain condi-
tions [17]. Besides the obvious implications of the pres-
ence of musculoskeletal pain in PSP on treatment, it
may also pose diagnostic difficulties due to the presence
of referred pain that commonly accompanies myofascial
pain syndromes. Despite its recognition as part of the
general PSP diagnostic possibilities, the prevalence of
MPS has never been characterized in patients with
CPSP. The identification of the co-occurrence of MPS
with CPSP pain is of major importance for two reasons:
first, using the current diagnostic criteria of neuropathic
pain [18], MPS pain can be erroneously considered as
neuropathic pain since it also refers to the presence of
pain in an area of somatosensory system lesion. Second,
and most important, it has been recently proposed that
CPSP should be a diagnosis of exclusion, since there
would be no pathognomonic feature of the syndrome
[19], being reserved for patients with PSP and without
other clear nociceptive or peripheral neuropathic pain
syndromes. Although apparently sound, this proposal
must be tested, since it is not known to which extent
CPSP overlaps with other PSP syndromes such as MPS.
We performed a cross-sectional standardized clinical
and radiological evaluation of patients with definite
CPSP in order to assess the presence of MPS in this
sample.
Methods
Forty CPSP patients were evaluated in the Pain Center
of the Hospital das Clínicas in the University of São
Paulo. All patients presented at least one stroke affecting
the somatosensory pathways, as documented by brain
MRI or CT scans.
Inclusion criteria were adults (> 18 years), presenting
definite neuropathic pain with sensory deficits in the
same topographic area related to a lesion to the somato-
sensory system [18]. Exclusion criteria were the presence
of pain of exclusive nociceptive or peripheral neuropatic
origin, the presence of major aphasia or other cognitive
deficit impairing the report of the sensory abnormalities
and pain characteristics.
Clinical evaluation
All patients signed an informed consent to participate in
the study. The protocol was approved by our local Ethics
Review Board. Patients were asked to keep current medi-
cations and were assured to have their treatment contin-
ued during and after the end of the study.
Data on associated health conditions, time between
stroke and pain onset, and duration of pain were
recorded during a structured interview.
Patients were instructed to indicate the site of their
neuropathic pain in a human body template and to iden-
tify the presence and location of the other painful areas.
Bedside physical examination was performed with the
following tests: vibration detection threshold was per-
formed with a 128 Hz vibrating tuning fork applied to
the first finger and to the toe bilaterally. Thresholds were
defined as the time elapsed from the beginning of the
exam to the point where the patients ceased to detect the
vibration stimulus. Hyperalgesia was assessed with a pin-
prick. Mechanical dynamic allodynia was assessed with a
soft brush slightly stroke for 6 cm 2 cm/sec. Tactile non-
painful stimulus was investigated with a cotton swab.
Thermal sensitivity was assessed with hot (40-45°C) and
cold (5-10°C) water-filled tubes. Thermal allodynia was
defined as the presence of pain to the contact of a glass
tube containing water at 20°C in the absence of mechan-
ical allodynia. Each sensory test was performed in prede-
termined cutaneous points five centimeters apart from
each other from the face to the feet bilaterally [20,21]
(Figure 1). MPS was searched for in a systematic manner
by gentle manual palpation of predefined muscles trigger
points. When palpation elicited the characteristic re-
gional referred pain from the muscle being tested, trigger
points were considered as active and MPS was defined
after the other diagnostic criteria were fulfilled [15,16].
The main muscles evaluated for MPS in CPSP patients
were defined according to a pilot study previously per-
formed in a similar group of patients. The location of the
active trigger points, the extension of sensory deficit and
the location of pain was marked and a human body tem-
plate by the examiner.
Pain intensity was assessed by the visual analogic scale
at the moment of the evaluation (VAS) [22]. The differ-
ent aspects of pain were measured by the McGill Pain
Questionnaire (MPQ) [23] adapted to the Portuguese
language [24]. Mood was assessed by the Beck depres-
sion scale [25].
Brain MRI was performed in 24 patients (65%) or CT
scan in 16 (35%). Lesions sites were classified as thal-
amic, thalamic-capsular, supratentorial extra-thalamic,
brain stem or undetermined by a blinded experienced
neuroradiologist. Patients with multiple encephalic
lesions were stratified according to main site of the le-
sion anatomically related to the sensory deficits.
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Areas of pain         , thermal-sensory abnormalities           and myofascial pain trigger points ( + ) in 40 
central poststroke pain patients.
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Figure 1 Pain area, thermal deficits and miofascial pain syndrome trigger points in central poststroke pain patients. Areas of pain (red),
thermo-sensory abnormalities (yellow) and myofascial pain trigger points ( + ) in 40 patients with central poststroke pain.
de Oliveira et al. BMC Neurology 2012, 12:89 Page 3 of 8
http://www.biomedcentral.com/1471-2377/12/89
Patients were on regular pharmacotherapy for pain con-
trol when data were collected. They used, as mono or
polytherapy, the following medications: heterocyclics anti-
depressants in 33 (82.5%) patients and anticonvulsants in
21 (52.5%) (Table 1). Regular physical therapy was per-
formed in 5 (12.5%) and acupuncture in 6 (15.0%).
Statistical analyses
Results are expressed as mean (± standard deviation) or
median (range) according to the distribution of the vari-
ables. Qualitative variables were analyzed according to
Fisher’s exact test. The χ2 test was used to compare the
proportions of patients with pyramidal signs and MPS.
Quantitative variables were analyzed by the Kruskall-
Wallis test, according to the normal distribution of the
data as assessed by the Shapiro-Wilk normality test. For
all tests significance was set at P < 0.05.
Results and discussion
Forty patients were evaluated (26 males, 59.5±10.7 years
old, ranging from 34 to 84 years old). Thirty-six (90.0%)
had ischemic stroke (s). Thirty (75.0%) patients had one
single and six (15%) had more than one ischemic vascu-
lar event. Three (7.5%) patients presented intra-cerebral
hemorrhage and one (2.5%) subarachnoid hemorrhage
followed by vasospasm in the territory of the left middle
cerebral artery. Thirty-four (85.0%) patients had systemic
arterial hypertension, 7 (17.7%) diabetis mellitus, 5
(12.5%) cardiopathy, 2 (5.0%) hypercholesterolemia, 1
(2.5%) migraine. Major neurologic deficits were motor
pyramidal motor syndrome in 17 (42.5%), cranial nerves
deficits in 6 (15.0%) cerebellar syndrome in 5 (12.5%),
choreoatetosic movements in 3 (7.5%), sensory ataxia in
two (5.0%) and hemianopsia in one (2.5%) patient.
Pain onset was insidious in 31 (77.5%) patients and
presented during the first three months after stroke in
30 (75.0%) (Table 1). Pain was reported in the whole
hemi-body in 22 (55.0%) patients, and had a multifocal
distribution in the remainder.
Median pain intensity according to VAS was 10 (5 to
10) and the average pain duration period was 5.73
(±4.39) years. There was no difference in pain intensity
among the different lesion site groups. Neuropathic pain
was continuous-ongoing in 34 (85.0%) patients and
intermittent in the remainder. Burning was the most
common descriptor (70%), followed by electric shock-
like paroxysms (22.5%). Nineteen (47.5%) patients had
more than one descriptor for their neuropathic pain.
Main aggravating factors were contact to cold (62.5%),
mood swings (52.5%), movement of the painful limb
(37.5%), and contact to heat (20%). There was more than
one aggravating factor in 33 (82.5%) patients (Table 1).
No statistically significant difference was found regard-
ing the descriptors of pain, aggravating factors, and the
MPQ scores among the lesion groups. Thermo-sensory
abnormalities were universal in the series and are
expressed on Table 2.
Painful shoulder syndrome was diagnosed in 4 (10.0%)
patients and shoulder-hand syndrome in 1(2.5%). MPS
was diagnosed in 27 (67.5%) patients and was more
common in the supratentorial extra-thalamic group
(P <0.001) (Table 3). It was more frequent in patients with
pyramidal deficits (82.35%) than those without it
(56.52%), however this difference was not statistically
significant (P= 0.017). The main muscles affected by
MPS in CPSP patients were presented on Table 4. The
spatial relationship between thermal deficits, pain and
MPS pain area for each patient is illustrated in Figure 1.
Autonomic abnormalities were found in 23 (57.5%) cases:
Horner’s sign was observed in 6 (15.0%) cases,
hypothermia of the upper and lower extremities in 10
(25.0%) patients, hyperemia in 9 (22.5%), edema in 5
(12.5%), hyperhydrosis in 2 (5.0%) and pallor in 2 (5.0%).
The mean score of the BDQ was 22.87±11.96. No sig-
nificant differences were observed among the different
stroke location groups and pain quastionaires and scales
scores. Importantly, CPSP patients with and without MPS
did not differ in pain intensity (VAS), MPQ or BDS
scores.
We performed a clinical-radiological evaluation of a
group of CPSP patients focusing on the co-occurrence
of PSP syndromes other than CPSP, in particular the role
of MPS in these patients. CPSP was diagnosed according
to the definite revised neuropathic pain criteria [18]. The
presence of thermo-sensory deficits in all patients is a
clinical hallmark of central pain, described in other
series [4,26-28]. We looked for the presence MPS in a
standardized fashion. MPS was present in the majority
of cases (67.5%), suggesting that “pure” neuropathic pain
syndrome is present in the minority of CPSP. Instead,
most patients had mixed pain syndromes in which cen-
tral neuropathic pain was associated with other syn-
dromes (nociceptive). It has been recently proposed that
CPSP should be a diagnosis of exclusion in PSP patients
[19]. Our data suggest that this proposal might lead to
under-diagnose of CPSP in PSP patients with associated
MPS. A clear limitation of the design of our study is the
lack of a control group. Evaluating the presence of MPS
in a PSP population without CPSP would help us to bet-
ter understand the factors influencing the occurrence of
MPS in PSP patients. However, even if PSP patients
without CPSP had a high prevalence of MPS, the preva-
lence of MPS in CPSP would still be quite high (as
shown here), suggesting that for nomenclature and def-
inition purposes CPSP should not be a diagnosis of ex-
clusion. Certainly, this assumption must be confirmed
by other larger studies, as well as the role of MPS in
pain treatment and rehabilitation in these individuals.
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Table 1 Patient’s demographics, types of stroke, past medical history, VAS, aggravating factors of pain, the presence
of motor deficits, MPS and medications in 40 patients with central poststroke pain
Patient Age Gender Stroke Past medical
hystory
VAS Aggravating factors Motor
deficits1
MPS Medications One year
follow-up
VAS
1 65 male Ischemic Hipertension 10 cold / movement /
mood swings
no no nortrip, CBZ,
methad
7
2 53 female Ischemic Diabetis 10 cold / mood swings yes yes amitrip, CBZ,
NSAID
8
3 60 male Ischemic Hypertension 8 cold / movements no no amitrip, GBP 2
4 65 female Ischemic 10 weather changes / cold no no nortrip, CBZ 8
5 69 male Ischemic 6 mood swings yes no amitrip, CBZ,
chlorpr
0
6 49 male Ischemic Hypertension 10 heat / mood swings yes yes GBP 8
7 63 female Ischemic Hypertension 9 cold /movements no no amitrip 4
8 54 male Ischemic Diabetis 10 mood swings no yes amitrip, CBZ,
GBP, tramadol
10
9 64 male Ischemic 10 cold / movements yes no imipramine, chlorpr 8
10 45 female Ischemic Hypertension 10 cold / mood swings no yes amitrip, sertraline,
CBZ, chlorpr
6
11 74 male hemorragic 8 cold / weather changes /
mood swings
yes yes amitrip 4
12 61 male Ischemic Hypertension 10 cold / weather changes /
movements
yes yes CBZ, cyclobenz 3
13 53 female Ischemic Cardiopathy,
diabetis
10 diabetis descompensation yes yes amitript 8
14 65 male Ischemic Hypertension 9 cold / heat / mood swings no yes nortrip 7
15 65 male Ischemic Hypertension 10 mood swings yes yes amitrip, chlorpr 5
16 65 male Ischemic 10 cold / movements /
mood swings
no yes amitrip, methad 6
17 34 female Ischemic 10 skin contact / movements no yes nortrip, chlorpr 8
18 67 male Ischemic Hypertension 9 cold / contact / movements no yes GBP 6
19 61 male Ischemic Cardiopathy 9 cold / mood swings yes yes nortrip, fluox,
baclof, CBZ
3
20 66 male Ischemic Hypertension 10 heat / cold yes no nortrip 5
21 59 female Ischemic Parkinson´s 10 mood swings no yes amitrip, chlorpr 6
22 40 male Ischemic Hypertension 10 cold / heat no no amitrip, GBP 9
23 41 male hemorragic Hypertension 10 cold / mood swings yes yes amitrip, CBZ, chlorp 10
24 78 female Ischemic Hypertension 5 cold / mood swings yes yes imipramin, chlorp 4
25 80 male Ischemic Diabetis 6 diabetis
descompensation / heat
yes yes amitrip, CBZ, chlorp 4
26 84 female Ischemic Hypertension 10 mood swings no yes amitrip, sertral,
bromazep
9
27 55 female Ischemic Hypertension 8 cold / movements no yes amitrip, chlorpr 5
28 63 female Ischemic 8 mood swings / movements no yes amitrip, sertral 5
29 60 male Ischemic 8 sexual activity / movements no yes clomipramine, CBZ 8
30 56 male Ischemic Hypertension 8 cold / heat no yes amitrip, chlorpr 6
31 64 male Ischemic 7 cold / weather changes no no GBP 6
32 60 male Ischemic Migraine 6 cold / movement /
mood swings
no no CBZ 0
33 47 male Ischemic 10 cold / weather changes yes yes amitrip, GBP 8
34 64 male Ischemic Hypertension 7 mood swings / movements no no amitrip, CBZ 0
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Furthermore, the identification of a central neuropathic
element in a pain of musculoskeletal origin can be diffi-
cult and in some cases, several pain types might be
present in the same area of the body [19], the findings of
our study corroborate to this view. Motor deficits, spasti-
city, movements disorders and altered central descending
pain modulation [14,29] may all induce overload to the
muscles and trigger myofascial pain [2,4,5,8,10-12,27].
MPS in its turn can serve as peripheral generator of noci-
ceptive inputs that may alter pain perception, as has been
suggested to occur in other chronic pain conditions [17].
MPS was more frequent in supratentorial extra-thalamic
(92.9%) and thalamic-capsular (100%) subgroups when
compared with thalamic (50.0%) and brain stem (37.5%)
stroke groups. This finding could be a consequence of
the magnitude of the motor deficits and spasticity; how-
ever, we found no association on the presence of pyram-
idal deficits and the presence of MPS. Many patients in
the supratentorial extra-thalamic group presented exten-
sive brain lesions, usually secondary to occlusion of
major arteries, resulting in major motor deficits, postural
abnormalities, hypertonia and spasticity. This is further
supported by the finding that 4 of the 8 patients in the
thalamic group had an infarction located in the territory
of the thalamic-geniculate artery, encompassing most of
the sensory pathways while preserving motor cortical-
spinal fibers [30,31].
To our best knowledge, the prevalence of MPS in
patients with CPSP has not been described previously.
Interestingly, the presence of MPS was not associated
with more intense pain or pain associated mood disor-
ders in CPSP patients, however, this can be due to some
limitations of the study, such a small number of patients
and a ceiling effect related to the high pain intensity of
these highly refractory individuals. Also, we did not
quantify the intensity of MPS, which could help better
understand its relationship to pain intensity and disabil-
ity. In our sample of CPSP individuals the mean pain
duration period was high (5.73 years), the pain scores, as
well as the depression rates, were elevated, indicating a
condition of high chronicity, psychosocial stress and re-
fractoriness to treatment. The limited access of the
stroke patients to a physical therapy program, performed
in only five (12.5%) patients could have increased the in-
cidence of MPS in this series. Moreover, a comparative
analysis of the CPSP series with a control group was not
Table 1 Patient’s demographics, types of stroke, past medical history, VAS, aggravating factors of pain, the presence
of motor deficits, MPS and medications in 40 patients with central poststroke pain (Continued)
35 51 male Ischemic Diabetis 9 cold / heat yes yes amitrip, cyclobenz 7
36 42 female hemorragic 9 mood swings no yes amitript 8
37 61 female Ischemic Hypertension 10 cold / movement yes yes GBP, nortrip 7
38 54 male Ischemic 10 mood swings / movements yes yes GBP 8
39 67 female hemorragic dislipidemia 10 cold / heat no no amitript 9
40 58 male Ischemic Hypertension 7 mood swings no no amitript 5
MPS=miofascial pain syndrome, 1 = pyramidal motor deficits, amitrypt = amitryptiline, nortrypt = nortriptiline, CBZ = carbamazepine, GBP = gabapentin,
chlorpr = chlorpromazine, fluox = fluoxetine, sertral = sertraline, methad =methadone.
Table 2 Sensory abnormalities according to the location of encephalic lesions in CPSP patients
Sensory changes Lesion site
Th ThC SETh BrS Und Total
Heat and cold hypoesthesia 6 (75.0) 5 (100.0) 14 (100.0) 7 (87.5) 5 (100.0) 37 (92.5)
Heat and cold hyperesthesia 1 (12.5) - - - 1 (2.5)
Cold hyperesthesia and heat hypoesthesia 1 (12.5) - - 1 (12.5) - 2 (5.0)
Hypalgesia 5 (62.5) 4 (80.0) 12 (85.7) 6 (75.0) 3 (60.0) 30 (75.0)
Hyperalgesia 3 (37.5) 1 (20.0) 2 (14.3) 1 (12.5) 2 (40.0) 9 (22.5)
Hyperpathia 6 (75.0) 4 (80.0) 11 (78.6) 5 (62.5) 3 (60.0) 29 (72.5)
Reduced vibration sensitivity 6 (75.0) 3 (60.0) 14 (100.0) 2 (25.0) 3 (60.0) 28 (70.0)
Tactile allodynia 3 (50.0) 3 (60.0) 10 (71.4) 4 (50.0) 2 (40.0) 22 (57.9)
Thermal allodynia 1 (12.5) 4 (80.0) 7 (50.0) 3 (37.5) 3 (60.0) 18 (45.0)
Kinestesic allodynia - - 3 (21.4) - - 3 (7.5)
TOTAL 8 5 14 8 5 40 (100)
Results are expressed as number (%). Th: Thalamic; ThC: Thalamic-capsular; SETh: Supratentorial extra-thalamic; BrS: Brain Stem; Und: Undetermined. CPSP: Central
Post-Stroke Pain.
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performed. Still, our data suggest that MPS should be
viewed as a common comorbid condition co-occurring
with the CPSP syndrome complex. Similarly, we found
painful shoulder in four (10.0%) patients and shoulder-
hand syndrome in one (2.5%). Shoulder-hand syndrome is
caused by glenohumeral joint subluxation due to motor
paresis and is commonly associated with painful shoulder
and is one of the possible presentations of the complex
regional pain syndrome in PSP patients [12,32,33]. Auto-
nomic abnormalities were found in 57.5% of our patients.
Many CPSP patients present motor deficits and avoid
movement of painful parts of the body. Prolonged
immobilization may induce sensory, neurovegetative,
motor and trophic abnormalities that can worsen pain
and induce complex regional pain syndrome, a condition
associated with neurovegetative abnormalities. [33,34]
Autonomic dysfunction can also be related to the en-
cephalic lesion such as lateral medullary stroke and Wal-
lenberg´s Syndrome in 4 (10.0%) patients.
Neurological deficits add more suffering to that
already caused by pain and psychosocial problems
related to handicap. Chronic suffering and incapacitation
often lead to, or facilitate the onset of depression. There
is a close relationship between pain and depression
[35,36] and the occurrence of depressive states in stroke
patients is a well-known phenomenon [10,37]. Leijon
et al. [10] reported higher incidence of depression in
CPSP patients than in a control group. Andersen et al.
[28] found no positive correlations for depression when
stroke patients with somatosensory deficits with and
without CPSP were compared. In our series, the mean
score of the BDQ was 22.87 and the prevalence of mod-
erate and severe depressive states were high. Recogniz-
ing and treating this condition is equally important if
one takes into consideration that central pain can fur-
ther increase the negative impact of depression on qual-
ity of life and increase the suicide risk [38].
Conclusions
We diagnosed MPS in more than two thirds of CPSP
patients. It was more common in patients with lobar
and thalamic-capsular lesions although no association
was found between motor deficits and a higher preva-
lence of MPS. The presence of MPS is not an exception
in CPSP and may represent a common comorbid condi-
tion. The impact of MPS in pain treatment, prognosis
and its role in rehabilitation of these patients remain to
be determined. Our results should provide insights on
the current diagnostic criteria of CPSP and draw atten-
tion to the different pain syndromes in the PSP syn-
drome complex.
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Table 3 Presence of Myofascial Pain Syndromes
according to stroke location
MPS present MPS absent Total p
Th 5 (50%) 5 (50%) 10 (25%) n.s.
ThC 0 (0%) 5 (100%) 5 (12.5%) n.s.
SETh 1 (7.1%) 13 (92.9%) 14 (35%) P <0.001
BrS 5 (62.5%) 3 (37.5%) 8 (20%) n.s.
Und 3 (60%) 2 (40%) 5 (12.5%) n.s.
Total 13 (32.5%) 27 (67.5%) 40 (100%) n.s.
Results are expressed as number (%). Th: Thalamic; ThC: Thalamic-capsular;
SETh: Supratentorial extra-thalamic; BrS: Brain Stem; Und: Undetermined.
Table 4 Muscles affected by Myofascial Pain Syndrome in
Central Post Stroke Pain Patients
Muscle Number of patients (%)
Scalenus 3 (7,5)
Sternocleidomastoideus 1 (2,5)
Splenius 12 (30)
Semispinalis 11 (27,5)
Trapezius 20 (50)
Levator scapulae 10 (25)
Supraspinatus 12 (30)
Infraspinatus 8 (20)
Pectoralis 8 (20)
Rhomboideus 10 (25)
Latissimus dorsi 1 (2,5)
Paravertebral dorsi 1 (2,5)
Paraverterbal lomborum 12 (30)
Quadratus lomborum 8 (20)
Deltoid 9 (17,5)
Biceps brachii 3 (7,5)
Triceps brachii 6 (15)
Brachioradialis 3 (7,5)
Glutaeus 6 (15)
Piriformis 7 (17,5)
Tractus ileospinalis / tensor fascia latae 5 (12,5)
Triceps surae 5 (12,5)
Tibialis anterior 3 (7,5)
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